Covadonga Pañeda
Chief Operating Officer chez ALTAMIRA THERAPEUTICS LTD.
Profil
Dr. Covadonga Pañeda is a Chief Operating Officer at Altamira Therapeutics Ltd.
Dr. Pañeda was previously employed as a Director-Development by LiMM Therapeutics SA and a Manager-Research & Development by Sylentis SA. She received her doctorate degree from Universidad Autónoma de Madrid.
Postes actifs de Covadonga Pañeda
| Sociétés | Poste | Début |
|---|---|---|
| ALTAMIRA THERAPEUTICS LTD. | Chief Operating Officer | 01/01/2023 |
Anciens postes connus de Covadonga Pañeda
| Sociétés | Poste | Fin |
|---|---|---|
LiMM Therapeutics SA
 LiMM Therapeutics SA Financial ConglomeratesFinance LiMM Therapeutics SA operates as a biopharmaceutical corporation, that specializes in molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. The firm develops medicines against inflammatory, infectious, and metabolic diseases. The company was founded by David Braga Malta and Henrique Veiga Fernandes and is headquartered in Paris, France. | Corporate Officer/Principal | 01/04/2022 |
Sylentis SA
 Sylentis SA BiotechnologyHealth Technology Sylentis SA develops new ophthalmic drugs and novel therapies based on RNAi (gene silencig) technology. The company is headquartered in Madrid, Spain. | Chief Tech/Sci/R&D Officer | 01/06/2018 |
Formation de Covadonga Pañeda
| Universidad Autónoma de Madrid | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALTAMIRA THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Sylentis SA
Sylentis SA BiotechnologyHealth Technology Sylentis SA develops new ophthalmic drugs and novel therapies based on RNAi (gene silencig) technology. The company is headquartered in Madrid, Spain. | Health Technology |
LiMM Therapeutics SA
LiMM Therapeutics SA Financial ConglomeratesFinance LiMM Therapeutics SA operates as a biopharmaceutical corporation, that specializes in molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. The firm develops medicines against inflammatory, infectious, and metabolic diseases. The company was founded by David Braga Malta and Henrique Veiga Fernandes and is headquartered in Paris, France. | Finance |
